The association between plasma Epstein-Barr virus (EBV) DNA titer dynamics and efficacy of anti–PD-1 monotherapy has been reported, while its value in predicting long-term outcomes and monitoring disease progression is unclear for patients with RM-NPC who are receiving anti–PD-1 monotherapy. The gene discussed is PDCD1; the disease is nasopharyngeal carcinoma.